Physician profile
William R Hurst
NPI 1538122858
$6,917.61
in general payments reported to CMS, 2019-2025
36 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $548 · 2021: $573 · 2022: $626 · 2023: $1,248 · 2024: $1,184 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,845.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,650.00 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,051.59 | 2019-2025 | |
| Novo Nordisk INC | $580.28 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $542.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $347.82 | 2021-2025 | Xifaxan |
| Amgen INC. | $347.09 | 2019-2025 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $330.21 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $295.28 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $201.39 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $174.62 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.34 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.04 | 2020-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $102.18 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $94.86 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $91.39 | 2022-2024 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $71.41 | 2020-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $69.64 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $69.63 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $59.40 | 2022-2024 | Eliquis |
| Abbott Laboratories | $51.87 | 2025 | Freestyle Libre 3 |
| Procept Biorobotics Corporation | $51.46 | 2023 | Aquabeam Robotic System |
| Genentech USA, INC. | $50.23 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.22 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.27 | 2019-2021 | |
| Allergan, INC. | $37.14 | 2019-2020 | |
| Shire North American Group INC | $36.17 | 2019 | |
| Scilex Pharmaceuticals INC. | $33.98 | 2025 | |
| Biosense Webster, INC. | $29.83 | 2019 | |
| Bausch Health US, LLC | $15.20 | 2019 | |
| Nabriva Therapeutics, Plc | $14.72 | 2022 | |
| Almatica Pharma LLC | $14.66 | 2023 | Loreev Xr |
| Assertio Therapeutics, INC. | $13.16 | 2019 | |
| Sanofi Pasteur INC. | $11.85 | 2019 | |
| Amarin Pharma, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.